SG11202111441QA - Bispecific antibodies against pd-1 and lag-3 - Google Patents

Bispecific antibodies against pd-1 and lag-3

Info

Publication number
SG11202111441QA
SG11202111441QA SG11202111441QA SG11202111441QA SG11202111441QA SG 11202111441Q A SG11202111441Q A SG 11202111441QA SG 11202111441Q A SG11202111441Q A SG 11202111441QA SG 11202111441Q A SG11202111441Q A SG 11202111441QA SG 11202111441Q A SG11202111441Q A SG 11202111441QA
Authority
SG
Singapore
Prior art keywords
lag
antibodies against
bispecific antibodies
bispecific
antibodies
Prior art date
Application number
SG11202111441QA
Inventor
Qiong Wu
Yong Zheng
Yunying Chen
Jing Li
Original Assignee
Wuxi Biologics Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuxi Biologics Ireland Ltd filed Critical Wuxi Biologics Ireland Ltd
Publication of SG11202111441QA publication Critical patent/SG11202111441QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
SG11202111441QA 2019-04-26 2020-04-24 Bispecific antibodies against pd-1 and lag-3 SG11202111441QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019084471 2019-04-26
PCT/CN2020/086830 WO2020216348A1 (en) 2019-04-26 2020-04-24 Bispecific antibodies against pd-1 and lag-3

Publications (1)

Publication Number Publication Date
SG11202111441QA true SG11202111441QA (en) 2021-11-29

Family

ID=72940870

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111441QA SG11202111441QA (en) 2019-04-26 2020-04-24 Bispecific antibodies against pd-1 and lag-3

Country Status (7)

Country Link
US (1) US20220213192A1 (en)
EP (1) EP3958900A4 (en)
JP (1) JP2022530496A (en)
KR (1) KR20220003567A (en)
CN (1) CN113727731B (en)
SG (1) SG11202111441QA (en)
WO (1) WO2020216348A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3768720A4 (en) * 2018-03-20 2022-01-05 Wuxi Biologics Ireland Limited Novel anti-lag-3 antibody polypeptide
TW202421193A (en) * 2022-09-28 2024-06-01 美商英塞特公司 Anti- pd-1/lag-3 bispecific antibodies and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103396481B (en) * 2013-07-18 2015-06-03 华南理工大学 Heavy chain single-domain antibody of type-II dengue fever virus NS1 protein as well as preparation method and application of heavy chain single-domain antibody
CN103665165B (en) * 2013-08-28 2016-02-24 江苏匡亚生物医药科技有限公司 Bi-specific antibody of a kind of targeted human CD47-SIRP signal α path and its production and use
SI3116909T1 (en) * 2014-03-14 2020-03-31 Novartis Ag Antibody molecules to lag-3 and uses thereof
TWI693232B (en) * 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
WO2016089610A1 (en) * 2014-12-06 2016-06-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bispecific antibody for cancer immunotherapy
JP6180663B2 (en) * 2014-12-23 2017-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Antibodies against TIGIT
TWI773646B (en) * 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 Lag-3-binding molecules and methods of use thereof
JP6878405B2 (en) * 2015-07-29 2021-05-26 ノバルティス アーゲー Combination therapy with antibody molecule against PD-1
KR102220275B1 (en) * 2015-11-18 2021-02-26 머크 샤프 앤드 돔 코포레이션 Pd1 and/or lag3 binders
MA45192A (en) * 2016-06-07 2019-04-10 Macrogenics Inc ASSOCIATION TREATMENT
WO2017215590A1 (en) * 2016-06-13 2017-12-21 I-Mab Anti-pd-l1 antibodies and uses thereof
KR102273634B1 (en) * 2016-09-21 2021-07-07 씨스톤 파마슈티컬즈 Novel monoclonal antibody against programmed death 1 (PD-1)
CN106279410B (en) * 2016-09-29 2019-08-20 华南理工大学 Two type dengue fever virus NS1 albumen multivalence nano antibodies of one kind and preparation method
TW201829462A (en) * 2016-11-02 2018-08-16 英商葛蘭素史克智慧財產（第二）有限公司 Binding proteins
JP7183163B2 (en) * 2017-01-06 2022-12-05 クレシェンド・バイオロジックス・リミテッド Single domain antibody against programmed cell death (PD-1)
CA3052532A1 (en) * 2017-04-05 2018-10-11 F. Hoffmann-La Roche Ag Bispecific antibodies specifically binding to pd1 and lag3
CN108948194B (en) * 2017-05-19 2023-02-17 上海药明生物技术有限公司 Novel CTLA-4 monoclonal antibody
EP3630292A2 (en) * 2017-05-24 2020-04-08 Sutro Biopharma, Inc. Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
EP3649156A1 (en) * 2017-07-06 2020-05-13 Merus N.V. Antibodies that modulate a biological activity expressed by a cell
US20200354460A1 (en) * 2017-09-29 2020-11-12 Wuxi Biologics Ireland Limited. Bispecific antibodies against EGFR and PD-1

Also Published As

Publication number Publication date
KR20220003567A (en) 2022-01-10
US20220213192A1 (en) 2022-07-07
EP3958900A1 (en) 2022-03-02
CN113727731B (en) 2023-06-02
CN113727731A (en) 2021-11-30
JP2022530496A (en) 2022-06-29
EP3958900A4 (en) 2023-01-25
WO2020216348A1 (en) 2020-10-29

Similar Documents

Publication Publication Date Title
IL279354A (en) Bispecific anti-psma x anti-cd28 antibodies and uses thereof
IL279974A (en) Bispecific anti-bcma x anti-cd3 antibodies and uses thereof
IL276340A (en) Pd-1 agonist antibodies and uses thereof
IL283493A (en) Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof
IL278844A (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
IL283530A (en) Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
EP3664829A4 (en) Pd-1 and pd-l1 binding agents
IL283945A (en) Bispecific anti-cd28 x anti-cd22 antibodies and uses thereof
IL275740A (en) Single-domain antibodies and variants thereof against pd-1
IL290255A (en) Anti-ctla4/anti-pd-1 bispecific antibody and use thereof
IL274438A (en) Single-domain antibodies and variants thereof against pd-l1
EP3634995A4 (en) Antibodies that specifically bind pd-1 and methods of use
EP3527590A4 (en) Anti-egfr and anti-cd3 bispecific antibody and applications thereof
IL275577A (en) Antibodies and variants thereof against pd-l1
EP3688034A4 (en) Bispecific antibodies against EGFR and PD-1
EP3833693A4 (en) Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
IL291482A (en) Bispecific antibodies against ceacam5 and cd3
EP3774917A4 (en) Single-domain antibodies against lag-3 and uses thereof
EP4003523A4 (en) Anti-pd-1/lag3/tigit trispecific antibodies and anti-pd-1/lag3 bispecific antibodies
EP3768727A4 (en) Novel bispecific pd-1/lag-3 antibody molecules
IL288692A (en) Bispecific antibody against α-syn/igf1r and use thereof
EP4245855A4 (en) Anti-tspan8-anti-cd3 bispecific antibody and anti-tspan8 antibody
SG11202103221QA (en) Anti pd-l1 antibody and use thereof
SG11202111441QA (en) Bispecific antibodies against pd-1 and lag-3
EP3710482A4 (en) Compositions and methods for making and using bispecific antibodies